Oxyspas
✅ Reduces bladder spasms
✅ Relieves urinary urgency
✅ Decreases urinary frequency
✅ Improves bladder control
✅ Treats overactive bladder
Oxyspas contains Oxybutynin Chloride.
✓ Medically reviewed by Morgan Ellis — Pharmacy Researcher · 8 years experience · Last reviewed: May 2026
Quick Answer — What is Oxyspas?
Oxyspas contains oxybutynin chloride — a tertiary amine anticholinergic / antimuscarinic drug used to treat overactive bladder (OAB) with symptoms of urgency, frequency, and urge incontinence. Available in 2.5 mg and 5 mg tablets. Oxybutynin is the oldest and most-prescribed OAB drug worldwide. It blocks M3 muscarinic acetylcholine receptors on the bladder detrusor, reducing involuntary contractions during filling. Standard adult dose: 5 mg two-to-three times daily (10-15 mg total/day); start at 2.5 mg twice daily in the elderly or anyone susceptible to anticholinergic side effects. Most common side effects: dry mouth (50%+), constipation, blurred vision, drowsiness, dizziness, urinary retention. Use with caution in adults aged 65+ — the 2023 American Geriatrics Society Beers Criteria classifies oxybutynin as “potentially inappropriate” in older adults due to anticholinergic-related fall, cognitive, and delirium risk. Mirabegron is the preferred first-line OAB drug in older patients.
📦 Every order is covered by our Reshipment Assurance Policy — if your parcel does not arrive within 20 business days, we reship it.
Why order from MedsBase
Every batch is sourced from a WHO-GMP certified manufacturer. Orders are dispatched in plain, unbranded packaging from our fulfilment partners and covered by our Reshipment Assurance Policy: if a parcel does not arrive within 20 business days we send a free reshipment, no questions asked.
What is Oxyspas?
Oxyspas is a brand of oxybutynin chloride immediate-release tablets, available in 2.5 mg and 5 mg strengths. Internationally branded as Ditropan (US, UK, EU, AU), Cystrin (UK), Lyrinel XL (extended-release), Oxytrol (transdermal patch), Gelnique (gel). Pack sizes available at MedsBase: 30, 60, 90 or 180 tablets per strength.
How oxybutynin works
Oxybutynin is a competitive antagonist at M1, M2 and M3 muscarinic acetylcholine receptors. The clinically relevant action is blockade of M3 receptors on the bladder detrusor smooth muscle — this reduces parasympathetic-driven detrusor contractions during the filling phase, decreasing urgency and incontinence episodes and increasing functional bladder capacity.
The dry-mouth, constipation, blurred-vision, and CNS side effects are the consequences of the SAME mechanism acting at non-bladder muscarinic receptors throughout the body — salivary glands (M3), gut (M2/M3), ciliary muscle of the eye (M3), and the central nervous system (M1/M2). Newer “uroselective” antimuscarinics (solifenacin, darifenacin) have somewhat better selectivity for bladder M3, but the difference is modest. Mirabegron, a β3 agonist with a completely different mechanism, avoids these side effects altogether.
When oxybutynin is used
- Overactive bladder syndrome (OAB) with urgency, frequency, urge incontinence — the licensed indication
- Neurogenic detrusor overactivity (multiple sclerosis, spinal cord injury, spina bifida)
- Nocturnal enuresis (bedwetting) in children >5 years — sometimes used as second-line after desmopressin
- Off-label: hyperhidrosis — occasionally used for excessive sweating because the same anticholinergic mechanism reduces sweat production. Side effects often outweigh benefit unless localised topical formulations are used.
Dosage & how to take
Adults:
- Standard starting dose: 5 mg twice daily; increase to 5 mg three times daily if needed (maximum 20 mg/day in younger patients)
- Sensitive or elderly: start at 2.5 mg twice daily and increase only if tolerated
- Take with or without food. Drink plenty of water.
- Effect on urgency develops within 1-2 weeks; full effect in 4-8 weeks
Children >5 years for nocturnal enuresis: 2.5-5 mg at bedtime, paediatric supervision essential.
Renal/hepatic impairment: reduce starting dose; titrate cautiously. Severe hepatic impairment is a relative contraindication.
Side effects & safety
- Very common (more than 1 in 10): dry mouth (the leading reason for discontinuation), constipation, dizziness
- Common: blurred vision (cyclopentolate-like effect), drowsiness, headache, nausea, urinary retention or hesitancy, palpitations, hot flushes, dry skin
- Less common: impaired heat tolerance (reduced sweating — risk in hot weather, exercise), confusion, hallucinations (especially in older adults), tachycardia
- Rare but serious: acute angle-closure glaucoma (in predisposed individuals), severe constipation / paralytic ileus, urinary retention, allergic angioedema, QT prolongation
- In elderly: increased falls risk, cognitive slowing, delirium, possibly increased long-term dementia risk — see geriatric section below
Anticholinergic burden & the elderly
Oxybutynin is the most strongly anticholinergic of the OAB drugs and crosses the blood-brain barrier readily. In adults aged 65+, the cumulative anticholinergic burden from oxybutynin (often combined with other anticholinergics in the medication list) is associated with measurable cognitive decline, increased fall risk, and emerging evidence of long-term dementia risk in observational studies.
Practical implications:
- If you are 65+ and starting OAB therapy, ask your doctor about mirabegron first — it has equivalent efficacy without the anticholinergic burden
- If oxybutynin is essential, use the lowest effective dose and consider transdermal or topical formulations (lower CNS exposure)
- Audit your full medication list for other anticholinergics (diphenhydramine, hydroxyzine, amitriptyline, quetiapine, tolterodine, hyoscyamine) — deprescribe where possible
- Review at 6-12 months: is the benefit worth the side-effect cost?
Contraindications & warnings
Do not take oxybutynin if you have:
- Untreated narrow-angle glaucoma
- Urinary retention or significant bladder outlet obstruction
- Severe gastrointestinal motility disorders (paralytic ileus, severe ulcerative colitis, toxic megacolon)
- Myasthenia gravis
- Hypersensitivity to oxybutynin
Use with caution if you have: elderly age (see above), benign prostatic hyperplasia (urinary retention risk), reflux oesophagitis, autonomic neuropathy, hyperthyroidism, coronary artery disease, hypertension, arrhythmia, dementia or cognitive impairment.
Pregnancy and breastfeeding: use only if benefit outweighs risk.
Drug interactions
- Other anticholinergics — additive effects; minimise stacking. Common offenders: diphenhydramine, hydroxyzine, amitriptyline, nortriptyline, paroxetine, quetiapine, hyoscyamine, scopolamine, tolterodine, atropine
- CNS depressants (alcohol, benzodiazepines, opioids) — additive sedation
- Cholinesterase inhibitors (donepezil, rivastigmine, galantamine for dementia) — OPPOSING mechanisms; co-prescribing both is irrational and the combination is associated with worse outcomes than either alone
- Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) — increase oxybutynin levels
- Drugs delayed by reduced GI motility — absorption may be altered (sustained-release formulations, levodopa)
How oxybutynin compares
| Drug | Class | Notable feature |
|---|---|---|
| Oxybutynin | Anticholinergic (M1-M3) | Cheapest, most prescribed; highest dry mouth + cognitive risk |
| Tolterodine / Terol LA | Anticholinergic | Better-tolerated than oxybutynin; LA form once daily |
| Solifenacin / darifenacin | Selective M3 anticholinergic | Slightly less dry mouth than oxybutynin |
| Mirabegron (Mirago) | β3 agonist | Preferred first-line in 65+; no anticholinergic burden |
| Flavoxate (Urispas) | Antispasmodic | Mild; useful for urinary spasm post-procedure |
Storage & shelf life
Store Oxyspas tablets below 25°C in the original blister pack. Protect from moisture and light. Keep out of reach of children. Do not use after the expiry date.
Frequently Asked Questions
Why does oxybutynin cause such bad dry mouth?
Oxybutynin blocks the M3 muscarinic receptors that drive saliva production in the salivary glands — the same receptor it blocks in the bladder. The dry mouth is a direct extension of the wanted bladder effect to an unwanted side. Sugar-free chewing gum, frequent sips of water, and a saliva substitute (Biotene, Glandosane) help. If dry mouth is intolerable, switching to mirabegron (no antimuscarinic effect) is usually the right move.
Should I take oxybutynin if I am over 65?
The 2023 American Geriatrics Society Beers Criteria classifies oxybutynin as “potentially inappropriate” in older adults — cumulative anticholinergic burden is associated with falls, cognitive slowing, delirium, and possibly long-term dementia risk. Discuss mirabegron first with your doctor; it has equivalent efficacy for OAB with none of these side effects. If oxybutynin is essential, use the lowest effective dose and review the rest of your medications for other anticholinergics that could be deprescribed.
How quickly does oxybutynin work?
Initial reduction in urgency and frequency is typically noticeable within the first week, with the full effect over 4-8 weeks. If there is no benefit by 8 weeks at maximum tolerated dose, switching to a different OAB drug (mirabegron, solifenacin, tolterodine LA) is reasonable.
Can I drink alcohol with oxybutynin?
Alcohol amplifies the drowsiness and dizziness side effects. Moderate occasional alcohol is generally fine but heavy or regular use is best avoided.
Will oxybutynin affect my driving?
Drowsiness and blurred vision can affect driving, especially in the first few weeks. Avoid driving until you know how oxybutynin affects you.
Why am I overheating in summer?
Oxybutynin reduces sweating (anticholinergic effect on sweat glands), so you can become unable to thermoregulate properly in hot weather or with exercise. Stay well-hydrated, avoid extreme heat, and consider switching to mirabegron if you live in a hot climate or do strenuous outdoor activity.
Can I take oxybutynin with my dementia drugs (donepezil, rivastigmine)?
This is a common but problematic combination — oxybutynin (anticholinergic) directly opposes the mechanism of donepezil/rivastigmine/galantamine (cholinesterase inhibitors that increase acetylcholine). Studies show worse cognitive outcomes when both are co-prescribed than with either alone. If both seem necessary, discuss with your doctor whether to switch the OAB drug to mirabegron.
Is the 2.5 mg or 5 mg strength right for me?
Most adults start at 5 mg twice daily. Older patients, those who weigh under 50 kg, those with renal/hepatic impairment, and anyone susceptible to anticholinergic side effects start at 2.5 mg twice daily and increase only if tolerated. The 2.5 mg strength of Oxyspas allows this gentler titration without splitting tablets.
Where can I order Oxyspas online?
You can order Oxyspas 2.5 mg or 5 mg tablets from MedsBase in pack sizes of 30, 60, 90 or 180 tablets. Orders ship worldwide with discreet packaging. Oxybutynin is specialist-supervised worldwide.
Related Alternatives
Other products in General Health that customers also view:
More options in Bladder Prostate
Ranked by recent MedsBase order volume — what other customers in this category are picking.
| Strength | 2.5 mg, 5 mg |
|---|---|
| Quantity | 30 Tablet/s, 60 Tablet/s, 90 Tablet/s, 180 Tablet/s |
Oxyspas
Frågor & svar
Oxyspas
Relaterade produkter
Recensioner
Det finns inga recensioner än